 Breda, the Netherlands August 2 5 , 2021 argenx Euronext Nasdaq: ARGX, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that it has submitted, and the European Medicines Agency EMA has validated, the marketing authorization application MAA for the Companys investigational FcRn antagonist, efgartigimod, for the treatment of generalized myasthenia gravis gMG. Validation of the MAA confirms that the application is sufficiently complete to begin the formal review process. 